Objective To demonstrate the potential of de-identified clinical data from multiple healthcare systems using different electronic health records (EHR) to be efficiently used for very large retrospective cohort studies. Materials and methods Data of 959 030 patients, pooled from multiple different healthcare systems with distinct EHR, were obtained. Data were standardized and normalized using common ontologies, searchable through a HIPAA-compliant, patient de-identified web application (Explore; Explorys Inc). Patients were 26 years or older seen in multiple healthcare systems from 1999 to 2011 with data from EHR. Results Comparing obese, tall subjects with normal body mass index, short subjects, the venous thromboembolic events (VTE) OR was 1.83 (95% CI 1.76 to 1.91) for women and 1.21 (1.10 to 1.32) for men. Weight had more effect then height on VTE. Compared with Caucasian, Hispanic/Latino subjects had a much lower risk of VTE (female OR 0.47, 0.41 to 0.55; male OR 0.24, 0.20 to 0.28) and African-Americans a substantially higher risk (female OR 1.83, 1.76 to 1.91; male OR 1.58, 1.50 to 1.66). This 13-year retrospective study of almost one million patients was performed over approximately 125 h in 11 weeks, part time by the five authors. Discussion As research informatics tools develop and more clinical data become available in EHR, it is important to study and understand unique opportunities for clinical research informatics to transform the scale and resources needed to perform certain types of clinical research. Conclusions With the right clinical research informatics tools and EHR data, some types of very large cohort studies can be completed with minimal resources.
Discussion As research informatics tools develop and more clinical data become available in EHR, it is important to study and understand unique opportunities for clinical research informatics to transform the scale and resources needed to perform certain types of clinical research. Conclusions With the right clinical research informatics tools and EHR data, some types of very large cohort studies can be completed with minimal resources.
BACKGROUND AND SIGNIFICANCE
As the use of electronic health records (EHR) in clinical care grows, so does the potential for using EHR data for clinical research. Advanced EHR are used by an estimated 1.5% of hospital 1 and 4% of ambulatory 2 practices. The percentage has grown over the past decade and is expected to continue to grow because of initiatives such as the American Recovery and Reinvestment Act. 3 Some EHR already have millions of patients' clinical data in their systems spanning more than a decade, including the Veterans Administration's Veterans Health Information Systems and Technology Architecture (VISTA) and several commercial EHR vendors.
Clinical research informatics, first referenced in 2006, describes the field of informatics, which includes EHR for use in clinical research. 4 As clinical data in EHR expand, their potential value for clinical research also increases. However, to be useable, standards must be in place and the data need to be standardized, normalized and aggregated. Systems must be developed that allow researchers relatively easy access to the data, ideally in real time/near real time, in a way consistent with the Health Insurance Portability and Accountability Act (HIPAA) 5 and the Health Information Technology for Economic and Clinical Health (HITECH) Act. 6 Standard ontologies (formal representations of knowledge) already exist for various types of clinical information that occur in EHR. The National Library of Medicine has collected many of these clinical information ontologies into the unified medical language system (UMLS). 7 UMLS contains a meta-thesaurus that describes and links various clinical informatics standard ontologies including Current Procedural Terminology (CPT) (for procedures), International Classification of Diseases 9th edition (ICD-9) and 10th edition (for diagnoses), logical observation identifiers names and codes (LOINC) (for laboratory information), Medical Subject Headings (MeSH) (for medical topics), RxNorm (for pharmacy information), and Systematized Nomenclature for Medicine -Clinical Terms (SNOMED-CT) (for medical terms). These standard ontologies form the basis on which to standardize, normalize and aggregate clinical information from different EHR.
Although the theoretical informatics infrastructure exists to standardize, normalize and aggregate clinical information from different EHR, efforts to date have not succeeded in integrating EHR data into a readily usable, scalable platform for clinical research in real time or near real time, especially across different healthcare systems with different EHR. Conceptually, from a technology perspective, standardized and normalized data from different healthcare systems could be aggregated as identified (ie, contains protected health information) or de-identified data. However, as a practical matter, many institutions, especially in the same healthcare market, do not always want to share identifiable data and legitimate privacy concerns exist with sharing identifiable data, even limited datasets. Totally de-identified data remove these issues, but limit the types of clinical research that can be done. However, de-identified data are not subject to the same HIPAA and institutional review board issues as identified data or even limited datasets that include protected health information. Therefore, some barriers to the use of clinical data are significantly reduced if de-identified data can be used.
Here, we demonstrate a clinical research informatics tool that uses UMLS ontologies to standardize, normalize and aggregate clinical data from multiple, distinct EHR across several different healthcare systems. The data are de-identified and presented through a secure web interface usable by researchers. The data are updated automatically at least once every 24 h. In particular, we present a retrospective cohort study of patient characteristics associated with venous thromboembolic events (VTE) (pulmonary embolisms (PE) and deep venous thrombosis (DVT)). This example demonstrates how, for particular types of clinical research, an appropriate clinical research informatics tool can be used to conduct very large scale cohort studies with minimal resourcesdtime, money, and personnel.
OBJECTIVE
To demonstrate, in a particular case example, the potential of de-identified clinical data from multiple healthcare systems using different EHR to be efficiently used for very large retrospective cohort studies.
MATERIALS AND METHODS
De-identified data were obtained using the Explore application on the Explorys Inc. platform (figure 1). The Explorys technology platform utilizes a health data gateway (HDG) server behind the firewall of each participating healthcare organization. The HDG server collects data from a variety of health information systemsdEHR, billing systems, lab/tests systems, etc. Next, the de-identified data from each participating healthcare organization are passed into the Explorys data grid, a private cloud-based datastore. The data are then standardized and normalized. Each participating healthcare organization has access to a secure web-based application, which allows for the searching and analysis of the data from all participating healthcare organizations. The data are automatically updated at least once every 24 h.
At the time of this study, the Explorys platform contained inpatient and outpatient information on several million patients from multiple, distinct healthcare systems and thousands of healthcare providers. These healthcare systems use the EHR as the primary medical record within their institutions. All data used from Explorys were de-identified to meet HIPAA and HITECH standards. In addition, in Explorys, all patient records have been mapped into a single set of UMLS ontologies to facilitate searching and indexing. Diagnoses, findings, and procedures are mapped into the SNOMEDeCT hierarchy. 8 Prescription drug orders are mapped into SNOMED (to represent the pharmacological class) and RxNorm (to represent the drug itself). 9 Laboratory test observations are mapped into the LOINC hierarchy established by the Regenstrief Institute. 10 On average, at the time of the study, each patient had a clinical record covering a span of 1280 days, with a range of 1 day to 4377 days over 12 years from 1999 to 2011.
Using the Explorys Explore application, we identified an aggregated patient cohort of eligible patients with a VTE (DVT or PE), based on SNOMEDeCT codes and compared these patients with eligible patients without a VTE. Eligibility criteria included age of 26 years or older with a height between 115 cm and 199 cm (women) or between 140 cm and 207 cm (men). Body mass index (BMI) groups were defined as those being below 25 kg/m 2 (normal weight), between 25 kg/m 2 and less than 30 kg/m 2 (overweight), and 30 kg/m 2 or greater (obese). First BMI and most recent height recorded in the EHR were used (first BMI and most recent height were chosen as patients were most likely to gain weight and lose height over time, so choosing these values would bias towards the null hypothesis). VTE patients were defined as those having either a SNOMEDeCT diagnosis of DVT or PE with an RxNorm prescription of either a thrombolytic agent or a direct-acting anticoagulant. A SNOMEDeCT diagnosis of DVT includes deep thrombophlebitis, thrombophlebitis of iliac vein, and phlegmasia alba dolens. A SNOMEDeCT diagnosis of PE includes obstetric PE, pulmonary air embolism, and pulmonary fat embolism. Table 1 depicts the mapping between SNOMEDeCT and ICD-9 codes. The thrombolytic agent pharmaceutical class includes deoxyribonucleases (RxNorm C0011522), drotrecogin alfa (RxNorm C1170000), and plasmin (RxNorm C0992337). The direct-acting anticoagulant pharmaceutical class includes bemiparin (RxNorm C0916062), dalteparin (RxNorm C0206461), and enoxaparin (RxNorm C0206460). Death rate was the percentage of patients in the study population who died during the study period and was determined by cross-referencing patient information with the Social Security Death Index, which is built into the Explorys Explore application.
Smoking status was determined through a self-reported field in the EHR and indicates smoking prevalence. A smoker was considered to be anyone who indicated that they were a smoking in the EHR at any time during the study period. Smoking status was not reported for 121 380 of the 959 030 patients in the study group (13%). Diabetes was determined by a SNOMED diagnosis of diabetes mellitus (SNOMED 191044006), as well as by an approach combining a SNOMED diagnosis of diabetes mellitus with the presence of at least one abnormal hemoglobin A1C (> 8%) and an outpatient prescription of at least one antidiabetic agent (including insulin, biguanides, and sulfonylureas).
Statistical calculations were conducted using R (V.2.12.1). Fisher's exact test was used to specify the 95% CI. The CochraneArmitage test was used to determine the p values for trends. For HIPAA-compliant statistical de-identification purposes, the Explorys Explore tool does not allow reporting on sample sizes less than 10 and all population counts above 10 are rounded to the nearest 10.
This study was deemed not to be human studies research by the institutional review board of the MetroHealth System because it involved only de-identified population-level data that conformed to HIPAA standards regarding the 18 types of information requiring special care. Business affiliation agreements were in place between all participating healthcare systems and Explorys Inc. regarding contribution of EHR data to the Explorys platform and the use of these de-identified data.
RESULTS
There were 21 210 incident VTE during an estimated 3.36 million patient-years (959 030 unique eligible patients followed for a mean of 3.5 years each). The overall crude incidence rate of VTE was 6.3 per 1000 person-years. Baseline characteristics across BMI categories are presented in table 2. In women, 38% were considered normal weight, 26% overweight and 35% obese.
For men, the corresponding distribution was 24% normal, 41% overweight and 36% obese.
Sex-specific OR for VTE by grouping of BMI and body height are shown in tables 3 and 4. Table 3 shows the impact of body height within each BMI stratum and the joint effects of BMI and body height on the odds of VTE, using normal-weight subjects with a short stature as the reference group. Table 4 shows the impact of BMI within each height stratum and the joint effects of body height and BMI on the odds of VTE, compared with the same reference group. Overall, the effect of changing weight categories (table 4) is larger than the effect of changing height categories (table 3) on VTE OR and this weight effect is more prominent in women than men, with women also having overall higher rates of VTE then men. Obese, tall woman had a VTE OR of 1.83 (1.76 to 1.91) compared with normal BMI, short women. For men the VTE OR was 1.21 (1.10 to 1.32). When compared with same gender, normal BMI, short stature individuals, there is a statistically significant trend (p<0.001) with increasing combinations of height and BMI to increasing VTE risk.
We also analyzed the effect of race/ethnicity on the relationship between VTE and BMI and height (table 5) . Among men and women, Hispanic individuals had the lowest VTE rate (OR 0.47, 0.41 to 0.55 for women; 0.24, 0.20 to 0.28 for men as compared with Caucasian individuals), while African-American individuals had the highest rate of VTE (OR 1.83, 1.76 to 1.19 for women; 1.58, 1.50 to 1.66 for men compared with Caucasian individuals). This race/ethnicity trend persisted among the studied BMI and height categories with Caucasian individuals having generally two to three times the odds of VTE compared with Hispanic individuals, while African-American individuals had three to four times the odds of VTE compared with similarly-sized Caucasian individuals, regardless of gender (data not shown).
Although not included in the detailed VTE analysis, we also report on the study participants' smoking rates and rates of diabetes (table 2) . Diabetes rates based solely on the patient having an ICD-9 diagnosis code related to diabetes were two to three times more than the diabetes rates based on a combination of the patient having an ICD-9 diagnosis code, at least one abnormal hemoglobin A1C laboratory value and at least one RxNorm prescription for an antidiabetic medication.
In terms of the resources needed to conduct this study, the five authors (the entire research team) spent a total of approximately 125 h over 11 weeks from concept initiation to initial submitted manuscript. This time was broken down into approximately 20 h of planning and discussion meetings, 20 h designing the data query and querying the data, 50 h of data analysis, and 35 h of manuscript preparation.
DISCUSSION
Here, we present a clinical research study that demonstrates the association between patient characteristics, especially height and BMI, and VTEdDVT and PE. Although similar VTE results have been published, 11e18 earlier studies have been prospective cohort studies. This study demonstrates the potential of clinical research informatics tools to perform very large-scale retrospective studies with limited resourcesdtime, money, and peopledfor certain types of clinical research.
Overall, this study shows a positive correlation with VTE and increasing height and weight (BMI). BMI (weight) appears to play a more significant role than height in VTE. The overall incidence of VTE is higher in this study compared with some other studies, 11e18 but the percentage of patients who were overweight or obese and African-American was also higher, so a higher VTE rate is expected. The prospective studies investigating this associated between BMI, height, and VTE typically involved tens of thousands of patients and hundreds of VTE events. These studies typically spanned many years, some even more than a decade in which data were being collected specifically for the study. In this study, many hundreds of thousands of patients and tens of thousands of VTE events were investigated. Because this study relied on data collected as part of the normal course of care, the study itself did not involve any separate data collection and so could be performed in days/weeks, rather than years/decades. This study demonstrates both the potential and limitations of this type of clinical research informatics tool and pooled, de-identified, clinical data from multiple healthcare systems using different EHR. First of all, in order to determine if someone had a VTE, we relied on a diagnosis of PE and/or DVT in the EHR and treatment with thrombolytics or direct-acting anticoagulants as documented by an order for one of these medications in the EHR. We could not look at other measures such as imaging or autopsy results or signs and symptoms of a VTE, as these were not coded in structured digital data/ontologies and thus could not be used as natural language processing of text was not supported by Explorys at the time of the study. For statistical de-identification, we were only able to report on counts to the nearest 10. However, given the large sample size, this limitation should not have had any significant effect on the qualitative or even quantitative findings of this study. Finally, the length of time of people in our cohort was variable. Our study has patient data ranging from 1 day to 12 years, with the average patient having information in the EHR for 3.5 years. Because of our de-identified dataset we could only run analyses at the population level and did not have access to specific dates (diagnosis dates, death dates, etc.) or to specific information about individual patients. Therefore, for our statistical analysis we relied on odd ratios and the CochraneArmitage test. Also, we were not able to perform true regression analyses. The decision to use purely de-identified data was not a technological constraint. The Explorys platform used allows for the use of de-identified data, as well as limited dataset data through data governance mechanisms. However, to demonstrate the efficiency with which de-identified data can be used, as well as the constraints of this approach, de-identified data were used.
The data analysis for this research was performed over an 11-week period using existing pooled, de-identified data of approximately one million patients from EHR data, going back as far as 1999, from multiple healthcare systems with distinct EHR systems. This research was conducted over days/weeks, as opposed to years/decades, involving only five people part time, and with no direct costs. This approach relies on the underlying data infrastructure collected by thousands of clinicians as the normal part of clinical care. Other examples of large clinical, EHR-based datasets being used for research, including the Veterans Administration's EHR and the EHR of other countries with more universal healthcare systems, such as Canada and England, exist, although typically start with much more uniform/the same EHR. Data sources such as the University HealthSystem Consortium do not have the same richness (breadth or depth) of data. This example demonstrates the use of clinical data from disparate healthcare systems using different EHR in an expanded and novel way. The Explorys model as a clinical data repository solution appears more efficient to set up (weeks) and use than other solutions we are aware of and provides near real time (at least daily) data updates. The Explorys Explore tool used to perform this research is economic, accessible, and scalable for researchers whose institutions have joined the Explorys network. Sustainability of the infrastructure is ensured by a subsidized model. Healthcare institutions in the Explorys network can agree to contribute their de-identified data to be pooled with the de-identified data of other healthcare institutions. The pooled, de-identified data can be accessed by healthcare institutions in the Explorys network and can be used by Explorys to support large-scale de-identified aggregate-level analytics. In exchange for contributing data, healthcare institutions in the Explorys network have subsidized access to the Explorys Explore tool and the de-identified data accessible through the tool for non-commercial purposes at no direct cost. Explorys provides the HDG and all of the resources needed to standardize, normalize and aggregate a participating institutions' data also at no direct cost to the healthcare system. For the MetroHealth System, the integration onto the Explorys platform required approximately 8 weeks of Explorys staff time and occurred several months before initiating this study. Integration involved installing Explorys' HDG and standardizing, normalizing and aggregating approximately 200 data elements and over one billion data points from 11 years' worth of clinical data on over 750 000 unique patients. This clinical data repository model recognizes the inherent value/ commodity of clinical data that healthcare systems with significant digital data have and allows a mutually beneficial relationship whereby healthcare systems with digital clinical data can leverage that asset to enable third parties to provide services at no direct cost to the healthcare systems. This solution could thus be implemented efficiently and effectively by any healthcare system with significant digital data.
The study leveraged data that were already standardized and normalized, including demographic information (age, weight, height, gender) and based on standard ontologiesdprimarily diagnostic information (using ICD-9 codes) and medication information (using RxNorm). Other types of data that would lend themselves to this type of analysis include laboratory information (using LOINC). Types of data that would not lend themselves as well to this type of analysis include signs and symptoms, some types of social history such as sexual history, and physical exam findings, among other types of medical information that do not have associated medical ontologies; although Explorys supports many of these types of data through proprietary mapping strategies. Table 6 provides an overview of the data in the Explorys Datagrid tool.
Three keys to using this type of pooled, standardized, normalized and de-identified EHR data include: 1. Understanding data sourcesdunderstanding of the characteristics of the underlying EHR data sources, including a data dictionary and ontologies used. 2. Corroborating data findingsdinternal and/or external methods to corroborate retrospective EHR cohort study data and/or findings. For example, manual chart review of a sample of the EHR data (internal validation), or other studies demonstrating similar results (external validation), ideally coupled with a biologically plausible hypothesis. 3. Clinical data versus research datadrecognizing that retrospective EHR data were typically collected for clinical and not research purposes. Therefore, depending on the type of data, the quality may not meet typical research standards. In some cases, the large quantity of clinical data may help mitigate the fact that it was not collected with the higher precision and accuracy that can occur as part of a prospective research study.
As with all studies, this study and the underlying approach have limitations. First of all, as stated previously, this study relied on demographic information and other clinical (nonadministrative) information based on standard clinical informatics ontologies. Studies looking at other clinical information may not have underlying clinical informatics ontologies and so may not be amenable to this approach. Moreover, the clinical data were initially obtained for clinical and not specifically research purposes and so the accuracy may be less than data collected solely for research purposes. However, in our experience, height and weight data typically have less than a 1% error Billing information Billed amount with associated common procedural terminology codes and provider and insurance type (mapped to custom ontology) Demographic information Age, gender, race/ethnicity, insurance, religion, language, five digit zip code (mapped to custom ontology) Diagnosis information All structured problem list and encounter diagnoses entered into integrated health information systems (mapped to SNOMEDeCT ontology) Drug information All inpatient and outpatient medication orders entered into the integrated health information systems (mapped to RxNorm/SNOMED classification; includes pharmacology class, drug ingredient, generic drug/pack names, and brand names) Findings information ICD-9 concepts mapped to SNOMEDeCT, findings subgraph) History information Past medical history (mapped to SNOMEDeCT), past surgical history (mapped to SNOMED), and social history (tobacco and alcohol status) (mapped to custom ontology) Miscellaneous information Allergies (mapped to SNOMEDeCT), immunizations (mapped to SNOMEDeCT and RxNorm), health maintenance, implantable devices Observation information
All laboratory orders and results that are structured data in the integrated health information systems in addition to all non-laboratory orders entered into the integrated health information systems and some results that are structured data (eg, left ventricular ejection fraction) (mapped to LOINC multi-axial hierarchy) Procedure information Common procedure terminology codes and custom codes entered into the integrated health information systems (mapped to SNOMEDeCT ontology).
Provider information
Unique ID, specialty, department, role (mapped to custom ontology) Vital signs All heights, weights, blood pressures rate, 19 diagnosis coding for serious subacute and chronic disease such as VTE is very good (and our overall incidence of VTE is in the range of other studies), and medication prescribing (not patient taking the medication) is excellent in organizations with high rates of computerized physician order entry, such as the healthcare systems involved. Although Explorys does use a masterepatient identifier and did attempt to match the same patient across different healthcare systems and combine their data, some of the care of some study patients may have occurred outside the Explorys healthcare partners and some patients may be counted multiple times. However, the healthcare systems involved are large integrated delivery networks in northeast Ohio where the EHR is used for inpatient and outpatient care, so we suspect relatively few patients travelled between healthcare systems or received some care outside of their healthcare system, and it is not clear that any error in this area would disproportionately affect the VTE group more or less than the non-VTE group. In addition, Explorys uses a robust patient matching algorithm. Third, because of the de-identified nature of our dataset, including the inability to look at specific visit dates and death dates (because of HIPAA limitations on dates), we needed to use OR rather than logistic regression analysis and HR as opposed to Cox regression analysis. In spite of this limitation, qualitatively and quantitatively our results match those reported elsewhere. Finally, our inability to look at specific dates meant that our analysis focused on the prevalence of VTE throughout our 12-year study period (average patient with data over a 3.5-year (1280-day) period), as opposed to incidence in a particular year. Therefore, this study also did not distinguish between patients having one VTE versus multiple VTE.
CONCLUSION
Ultimately, in order to perform successful clinical research, a clinical question or hypothesis must be developed and then tested. Aggregated, standardized and normalized clinical data from different EHR, automatically updated in near real time (at least every 24 h), presented in a HIPAA and HITECH-compliant de-identified way, through a secure web interface, as demonstrated in our example, has the potential to allow population research with minimal resourcesdtime, people and money. As EHR continue to proliferate and collect vast volumes of clinical data, they will become an increasingly important data source for clinical research. We need to continue to develop, proliferate and utilize scalable clinical research informatics tools and methodologies to take full advantage of these burgeoning resources efficiently and effectively.
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